Supplementary Data File for "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis"
Published: 19 April 2024| Version 1 | DOI: 10.17632/bh6p4rk5j9.1
Contributors:
Steve Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadlo-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee RhoDescription
Supplementary Materials for the Paper "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis" that is published in the Journal of the American Academy of Dermatology (JAAD).
Files
Categories
Psoriasis, Randomized Clinical Trial, Therapeutic Equivalence, Monoclonal Antibody Therapy
Funders
- Samsung Bioepis Co., Ltd